JPMorgan Initiates Iambic Therapeutics Coverage at Overweight, Sets $22 Target

JPMorgan initiated coverage of Iambic Therapeutics at Overweight and set a $22 price target. The target implies 116.3% upside from the November 6 close of $10.17.